ASTH vs. ETON
ASTH (Astrana Health Inc) and ETON (Eton Pharmaceuticals Inc) are both stocks. Both are in the Healthcare sector — ASTH in Medical Care Facilities, ETON in Drug Manufacturers - Specialty & Generic. Over the past 5 years, ASTH returned -11.30%/yr vs 44.06%/yr for ETON. At a 0.15 correlation, their price movements are largely independent.
Performance
ASTH vs. ETON - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ASTH achieves a 88.94% return, which is significantly lower than ETON's 116.50% return.
ASTH
- 1D
- 0.14%
- 1M
- 21.37%
- 6M
- 64.88%
- YTD
- 88.94%
- 1Y
- 88.25%
- 3Y*
- 13.49%
- 5Y*
- -11.30%
- 10Y*
- 25.46%
ETON
- 1D
- -1.93%
- 1M
- 15.89%
- 6M
- 136.80%
- YTD
- 116.50%
- 1Y
- 152.66%
- 3Y*
- 121.47%
- 5Y*
- 44.06%
- 10Y*
- —
ASTH vs. ETON - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
ASTH Astrana Health Inc | 88.94% | -21.31% | -17.68% | 29.44% | -59.73% | 302.19% | -0.76% | -7.25% | 8.77% |
ETON Eton Pharmaceuticals Inc | 116.50% | 26.95% | 204.11% | 55.32% | -34.27% | -47.23% | 12.92% | 17.65% | -4.23% |
Correlation
The correlation between ASTH and ETON is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.18 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.19 |
Correlation (All Time) Calculated using the full available price history since Nov 13, 2018 | 0.15 |
Fundamentals
ASTH:
$2.32B
ETON:
$1.00B
ASTH:
$0.61
ETON:
-$0.05
ASTH:
0.66
ETON:
11.98
ASTH:
2.87
ETON:
37.72
ASTH:
$3.53B
ETON:
$86.93M
ASTH:
$238.21M
ETON:
$47.61M
ASTH:
$125.28M
ETON:
$5.70M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ASTH vs. ETON — Risk / Return Rank
ASTH
ETON
ASTH vs. ETON - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Astrana Health Inc (ASTH) and Eton Pharmaceuticals Inc (ETON). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ASTH | ETON | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.37 | ||
| Sortino ratioReturn per unit of downside risk | -1.22 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.40 | -0.11 |
| Calmar ratioReturn relative to maximum drawdown | 1.80 | 3.76 | -1.96 |
| Martin ratioReturn relative to average drawdown | 4.03 | 7.78 | -3.75 |
Loading charts...
Drawdowns
ASTH vs. ETON - Drawdown Comparison
The maximum ASTH drawdown since its inception was -84.80%, which is greater than ETON's maximum drawdown of -79.94%. Use the drawdown chart below to compare losses from any high point for ASTH and ETON.
Loading charts...
Drawdown Indicators
| ASTH | ETON | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -84.80% | -79.94% | -4.86% |
Max Drawdown (1Y)Largest decline over 1 year | -46.41% | -36.17% | -10.24% |
Max Drawdown (3Y)Largest decline over 3 years | -70.96% | -45.65% | -25.31% |
Max Drawdown (5Y)Largest decline over 5 years | -84.80% | -69.35% | -15.45% |
Max Drawdown (10Y)Largest decline over 10 years | -84.80% | — | — |
Current DrawdownCurrent decline from peak | -60.76% | -3.71% | -57.05% |
Average DrawdownAverage peak-to-trough decline | -47.19% | -37.26% | -9.93% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 20.73% | 17.52% | +3.21% |
Volatility
ASTH vs. ETON - Volatility Comparison
Astrana Health Inc (ASTH) has a higher volatility of 11.80% compared to Eton Pharmaceuticals Inc (ETON) at 9.15%. This indicates that ASTH's price experiences larger fluctuations and is considered to be riskier than ETON based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ASTH | ETON | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.80% | 9.15% | +2.65% |
Volatility (6M)Calculated over the trailing 6-month period | 48.63% | 40.37% | +8.26% |
Volatility (1Y)Calculated over the trailing 1-year period | 72.64% | 54.02% | +18.62% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 64.15% | 63.16% | +0.99% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 91.35% | 63.64% | +27.71% |
Dividends
ASTH vs. ETON - Dividend Comparison
Neither ASTH nor ETON has paid dividends to shareholders.
Financials
ASTH vs. ETON - Financials Comparison
This section allows you to compare key financial metrics between Astrana Health Inc and Eton Pharmaceuticals Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ASTH vs. ETON - Profitability Comparison
ASTH - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Astrana Health Inc reported a gross profit of 0.00 and revenue of 965.10M. Therefore, the gross margin over that period was 0.0%.
ETON - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Eton Pharmaceuticals Inc reported a gross profit of 14.74M and revenue of 24.27M. Therefore, the gross margin over that period was 60.7%.
ASTH - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Astrana Health Inc reported an operating income of 28.53M and revenue of 965.10M, resulting in an operating margin of 3.0%.
ETON - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Eton Pharmaceuticals Inc reported an operating income of 2.41M and revenue of 24.27M, resulting in an operating margin of 10.0%.
ASTH - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Astrana Health Inc reported a net income of 14.44M and revenue of 965.10M, resulting in a net margin of 1.5%.
ETON - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Eton Pharmaceuticals Inc reported a net income of 1.55M and revenue of 24.27M, resulting in a net margin of 6.4%.
Frequently Asked Questions
ASTH and ETON have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ASTH has higher volatility (11.80%) compared to ETON (9.15%). In terms of maximum drawdown, ASTH dropped -84.80% vs ETON's -79.94%.
ETON currently has the higher Sharpe Ratio (2.52 vs 1.15), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ASTH and ETON
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer